GlassScriptPhysician profile
Jasmine A Munoz
NPI 1942543665
$1,193.47
in general payments reported to CMS, 2019-2025
31 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $53.19 · 2021: $90.24 · 2022: $111 · 2023: $90.13 · 2024: $317 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $758.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $138.49 | 2024-2025 | Sublocade |
| Xeris Pharmaceuticals, INC. | $114.85 | 2024-2025 | Recorlev |
| Merck Sharp & Dohme LLC | $95.61 | 2019-2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $77.63 | 2022-2025 | |
| Pfizer INC. | $63.51 | 2024-2025 | |
| Coopersurgical, INC. | $56.13 | 2019-2022 | |
| Glaxosmithkline, LLC. | $55.22 | 2023 | Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $50.85 | 2019-2025 | |
| Organon LLC | $45.07 | 2022-2025 | Nexplanon |
| Abbott Laboratories | $41.69 | 2020-2021 | |
| Mannkind Corporation | $40.88 | 2021-2024 | |
| Braeburn INC. | $40.69 | 2025 | Brixadi |
| Sanofi Pasteur INC. | $37.10 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.34 | 2019-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.22 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $27.65 | 2019-2022 | |
| Becton, Dickinson and Company | $24.67 | 2019 | |
| Recordati_rare_diseases_inc. | $22.23 | 2025 | Isturisa |
| Daiichi Sankyo INC. | $19.77 | 2021 | |
| Sumitomo Pharma America, INC. | $19.07 | 2024 | Gemtesa |
| Radius Health, INC. | $19.03 | 2025 | Tymlos |
| Astellas Pharma US INC | $17.03 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.45 | 2024 | Voquezna |
| Cranial Technologies, INC | $16.20 | 2025 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $15.39 | 2024 | Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.89 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $14.59 | 2023 | Inpefa |
| Allergan, INC. | $14.03 | 2019 | |
| Mayne Pharma Commercial LLC | $12.86 | 2024 | |
| Ironwood Pharmaceuticals, INC | $11.83 | 2019 | |
| Athena Bioscience, LLC | $11.50 | 2023 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.